Increasing cancer survivorship means healthcare providers are encountering new challenges in cardiac health, underscoring the need for additional subspecialists in cardio-oncology.
Volumetric multispectral optoacoustic tomography (MSOT) could foster accurate characterization of the makeup of arterial plaque in real time, according to scientists.
Risk for atrial fibrillation, the most common heart rhythm disorder, increases with every cigarette a person smokes per day, according to a meta-analysis of nearly 30 prospective studies.
Women who give birth to infants with congenital heart defects (CHD) have a greater risk of developing cardiovascular disease (CVD) later in life than women whose babies do not have CHD, a Canadian study found.
Atrial fibrillation (AFib) patients who receive care from a cardiologist are about 32 percent less likely to die within the first year after initial diagnosis, a study published in the Canadian Journal of Cardiology found.
The use of statins for primary cardiovascular disease prevention in adults over age 75 is clouded in uncertainty. A recent study in the Journal of the American Geriatrics Society found that statins may significantly lower mortality risk in older adults. That only underscores the need for a large-scale, prospective, randomized clinical trial, researchers say.
Recent research based on data from Get With the Guidelines–Resuscitation (GWTG-R) shows a substantial decrease in the difference in survival rates between black and white patients who suffer in-hospital cardiac arrest.
Low serum calcium levels in the blood are associated with greater likelihood of sudden cardiac arrest (SCA), according to a study in Mayo Clinic Proceedings.
“Patients with serum calcium in the lowest quartile (<8.95 mg/dL) had...
Results from a Geisinger Obesity Institute study suggest Roux-en-Y gastric bypass (RYGB) surgery has durable protective effects with regard to congestive heart failure. This is the first time a study has shown such long-term benefits, according to researchers.
“Many studies have...
A major trial demonstrated the glucose-lowering drug empagliflozin reduces cardiovascular morbidity and mortality in individuals with Type 2 diabetes and existing cardiovascular disease. Clinicians and researchers discuss how it does so and who is most likely to benefit.
- 1 of 5
- next ›